Peripheral naïve CD8^(+)T cells as a predictive biomarker of response to lenvatinib plus an anti-PD-1 antibody in advanced hepatocellular carcinoma:a biomarker study  

作　　者：Cheng Huang Bin Xu Xiao-Dong Zhu Ying-Hao Shen Mei-Ling Li Jin-Jin Zhu Jian Zhou Jia Fan Hui-Chuan Sun 

机构地区：[1]Department of Liver Surgery and Transplantation,Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education,Liver Cancer Institute and Zhongshan Hospital,Fudan University,Shanghai 200032,P.R.China

出　　处：《Cancer Communications》2022年第11期1226-1230,共5页癌症通讯（英文）

基　　金：supported by the Leading Investiga-tor Program of the Shanghai municipal government(17XD1401100);the National Key Basic Research Program(973 Program,2015CB554005)from the Ministry of Science and Technology of China,the National Natural Science Foundation of China(81871929,82072667 to C Huang,81871928 to H-C Sun);the Special Research Fund for Liver Cancer Diagnosis and Treatment from the China Anti-Cancer Association(H2020-044 to C Huang,H2020-008 to H-C Sun).

摘　　要：Dear Editor,Most patients with hepatocellular carcinoma(HCC)are diagnosed at an advanced stage and are ineligible for rad-ical surgery[1].As anti-programmed cell death protein 1(PD-1)monotherapy has not shown promising anti-tumor effects in advanced HCC in first-line settings,combination therapy with targeted therapy plus immunotherapy,such as atezolizumab plus bevacizumab,has become the new first-line treatment for advanced HCC.Similarly,lenva-tinib combined with an anti–PD-1 antibody has shown an objective response rate(ORR)of around 40%in a phase I trial in advanced HCC[2].

关 键 词：HEPATOCELLULAR therapy surgery 

分 类 号：R735.7[医药卫生—肿瘤]